---
title: "BrightGene: Plans to repurchase shares worth 10 million to 20 million yuan, has repurchased nearly 3 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/263959658.md"
description: "BrightGene announced that on September 26, 2025, the company's board of directors approved the repurchase of shares through centralized bidding, intended for the employee stock ownership plan or equity incentives, with an expected repurchase amount of RMB 10 million to 20 million, and the repurchase period until September 25, 2026. As of October 31, 2025, the company had cumulatively repurchased 55,880 shares, accounting for 0.0132% of the total share capital, with a repurchase price of RMB 52.96 to 54.28 per share, and a total amount paid of RMB 2,993,933"
datetime: "2025-11-03T07:46:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263959658.md)
  - [en](https://longbridge.com/en/news/263959658.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263959658.md)
---

# BrightGene: Plans to repurchase shares worth 10 million to 20 million yuan, has repurchased nearly 3 million yuan

BrightGene announced that on September 26, 2025, the company's board of directors agreed to repurchase shares through centralized bidding for the employee stock ownership plan or equity incentive, with an expected repurchase amount of RMB 10 million to 20 million, and the repurchase period until September 25, 2026. As of October 31, 2025, the company had cumulatively repurchased 55,880 shares, accounting for 0.0132% of the total share capital, with a repurchase price of RMB 52.96 per share to RMB 54.28 per share, and a total payment of RMB 2,993,933

### Related Stocks

- [688166.CN](https://longbridge.com/en/quote/688166.CN.md)

## Related News & Research

- [02:32 ETBrightGene Announces Positive Topline Phase 1 Results of Oral BGM0504 in Obesity in China and the United States](https://longbridge.com/en/news/280422627.md)
- [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md)
- [China's Bio-Thera Gets US Nod for Golimumab Biosimilar](https://longbridge.com/en/news/286880573.md)
- [US working with small biotech firm on experimental Ebola treatment, Bloomberg News reports](https://longbridge.com/en/news/287108072.md)
- [Godrej Properties completes handover of 500+ plots at Forest Estate, Nagpur, with the first Nagpur edition of its signature handover IP, Shubh Aarambh](https://longbridge.com/en/news/286769958.md)